Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - norethisterone - oral tablet - 5mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - norethisterone - oral tablet - 5mg

Malta - Engels - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - norethisterone - tablet - norethisterone 5 mg - sex hormones and modulators of the genital system

Malta - Engels - Medicines Authority

wockhardt uk limited - norethisterone - tablet - norethisterone 5 mg - sex hormones and modulators of the genital system

Kenia - Engels - Pharmacy and Poisons Board

dawa limited p.o box 16633-00620 nairobi, kenya - norethisterone acetate - tablet - norethisterone acetate equiv. norethisterone 5mg - hormonal contraceptives: progestogens for

Malta - Engels - Medicines Authority

bayer limited 1st floor the grange offices the grange brewery road stillorgan co. dublin, a94 h2k7 , ireland - norethisterone - tablet - norethisterone 5 mg - sex hormones and modulators of the genital system

Malta - Engels - Medicines Authority

bayer plc - norethisterone - tablet - norethisterone 5 mg - sex hormones and modulators of the genital system

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of oestrogen deficiency associated with natural or artificial menopause (see dosage and administration and clinical trials).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of postmenopausal oestrogen deficiency (see dosage and administration and clinical trials). for the prevention of postmenopausal bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of kliogest should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. see precautions and dosage and administration. kliogest is for use in postmenopausal women with an intact uterus. in perimenopausal women treated with kliogest the incidence of vaginal bleeding is unacceptably high and therefore therapy should not be initiated sooner than one year after the last menstrual period.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 350 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - indications as at 9 march 2003 : noriday is an oral contraceptive for women who will not, or cannot tolerate other oral contraceptives or intrauterine devices.